name: "KSB-D09-K0030" description: "Personalized Medicine Applications: Subgroup identification algorithms, treatment effect heterogeneity assessment, precision medicine st..." version: "1.0.0" domain: "D09" domain_name: "Post-Authorization Studies" type: "Knowledge" proficiency_level: "L4" bloom_level: "evaluate" triggers: - "explain personalized medicine applications" - "what is personalized medicine applications" - "evaluate personalized medicine applications" epa_mapping: "EPA-02, EPA-04, EPA-05" cpa_mapping: "CPA-02, CPA-07" regulatory_refs: "FDA-STAT-001, FDA-CFR-006, EMA-GVP-009"
KSB-D09-K0030: Personalized Medicine Applications
Overview
Domain: D09 - Post-Authorization Studies Type: Knowledge Proficiency Level: L4 (Proficient - Independent practice) Bloom Level: Evaluate
Description
Subgroup identification algorithms, treatment effect heterogeneity assessment, precision medicine study designs
Context
- Major Section: Post-Authorization Study Design Framework and Methodological Foundation
- Section: AI-Enhanced Statistical Innovation and Methodology Development
EPA Mapping
- EPA-02:3004-3005
- EPA-04:3009-3010
- EPA-05:3011-3012
CPA Pathway
- CPA-02, CPA-07
Regulatory References
- FDA-STAT-001
- FDA-CFR-006
- EMA-GVP-009
Instructions
When this skill is activated, Claude should:
- Demonstrate L4 proficiency in personalized medicine applications
- Apply evaluate level cognitive skills to evaluate the topic
- Reference relevant regulatory guidance (FDA-STAT-001, FDA-CFR-006, EMA-GVP-009)
- Connect to related EPAs: EPA-02, EPA-04, EPA-05
Key Competencies
- Subgroup identification algorithms, treatment effect heterogeneity assessment, precision medicine study designs
Assessment Criteria
- Can evaluate core concepts independently
- Demonstrates understanding of regulatory context
- Applies knowledge appropriately to PV scenarios
Related Skills
- Other D09 skills in AI-Enhanced Statistical Innovation and Methodology Development
- Cross-domain integrations per DAG architecture
Generated from PV KSB Framework v1.0 | 2025-12-31